US pharma manufacturer enters Chapter 11 after failed takeover and FDA warnings
Aiming to seek an in-court sale of its business, international pharma company Akorn and its US subsidiaries have entered Chapter 11 following a failed takeover and multiple actions and warnings from the US’s Federal Drug Administration.
To read more
Subscribe to Global Restructuring Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Restructuring Review experts.